Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Adequate free flap perfusion during Deep Inferior Epigastric Perforator (DIEP) flap breast reconstruction surgery requires maintaining blood pressure above 100 mmHg and avoiding excessive fluid administration. This study aims to determine whether the use of a measurement of preload dependency (Pulse Pressure Variation = PPV), can guide fluid therapy and if it decreases the risk of flap oedema. For this purpose, two fluid management strategies will be compared:
For adequate free flap perfusion during Deep Inferior Epigastric Perforator (DIEP) flap breast reconstruction surgery, blood pressure must remain sufficiently high. General anaesthesia often induces systemic hypotension. To counteract this hypotension, the anaesthetist administers intravenous fluids (crystalloid fluids). However, fluid overload can lead to an increased risk of flap oedema and decreased flap perfusion and in exceptional cases to flap failure. To maintain blood pressure above 100 mmHg and to avoid excessive fluid administration, a vasopressor (norepinephrine) can be administered. This reduces the amount of fluids administered, thereby reducing the risk of flap oedema.
This study aims to determine whether the use of a measurement of preload dependency (Pulse Pressure Variation = PPV), can guide fluid therapy and if it decreases the risk of flap oedema. To this end, two fluid management strategies will be compared:
All included patients are randomized in a 1:1 ratio to the static (n = 41) or dynamic group (n = 41).
To treat hypotension in patients randomized to the 'static' group, fluid administration is limited to 5 ml/kg/h. When the maximum fluid volume is administered but blood pressure remains below 100 mmHg, norepinephrine is administered.
Treatment of hypotension in patients randomized to the 'dynamic' (= targeted fluid therapy) group, is guided by PPV. PPV is measured continuously during the surgery and if the blood pressure is below 100 mmHg, fluids are only administered if PPV is > 12%. If blood pressure is below 100 mmHg but PPV is < 12% (indicating no fluid is needed), norepinephrine is administered.
At the end of the procedure, 2 sensors are applied, these sensors provide information about the perfusion of the free flap during patient's stay in Intensive Care or the recovery room.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Static group | Active Comparator | When during surgery systolic blood pressure (SBP) is below 100mmHg:
When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg. When SBP remains below 100mmHg after reaching a vasopressor dose of 0.2mcg/kg/min: the anaesthetist can decide to give a bolus of 6mg ephedrine intravenous (IV) (with a maximum dose of 12mg ephedrine iv per hour). |
|
| Dynamic group | Experimental | After insertion of an arterial line, a pulse contour analysis system will be installed (Acumen IQ sensor, Edwards) for measuring PPV and cardiac index (CI). When during surgery SBP is below 100mmHg and PPV is above 12%: • give a fluid bolus (Plasmalyte A) until PPV is below or equal to 12% or SBP is above 100mmHg When during surgery SBP is below 100mmHg and PPV is below or equal to 12%: • start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min) When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg. When SBP remains below 100mmHg after reaching a vasopressor dose of 0.2mcg/kg/min, and CI is < 2.2 L/min/m², a bolus of 6mg ephedrine iv will be given (with a maximum dose of 12mg ephedrine iv per hour). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Plasma-lyte (static group) | Drug | Plasmalyte will be administered intravenously: (1) as a maintenance infusion 1ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until 5ml/kg/h crystalloid (without maintenance infusion) is reached or until SBP is above 100mmHg |
| Measure | Description | Time Frame |
|---|---|---|
| Total intraoperative fluid volume | Total intraoperative fluid volume (from anaesthesia induction until completed skin closure) | From anaesthesia induction until completed skin closure, assessed up to 12 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Cumulative perioperative fluid volume | Cumulative perioperative fluid volume (intraoperative fluid volume + fluid administered in the intensive care unit (ICU) or post-anaesthesia care unit (PACU)) | From anaesthesia induction until ICU/ PACU discharge, assessed up to 72 hours |
| Cumulative perioperative norepinephrine dose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Silvie Allaert, MD | Contact | +32 9 246 17 00 | silvie.allaert@mijnziekenhuis.be | |
| Ella Hermie, MSc | Contact | +32 9 246 17 03 | ella.hermie@mijnziekenhuis.be |
| Name | Affiliation | Role |
|---|---|---|
| Silvie Allaert, MD | AZ Maria Middelares Gent | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AZ Maria Middelares | Recruiting | Ghent | East Flanders | 9000 | Belgium |
Not provided
A monocentric, prospective, non-inferiority, randomised controlled trial. Interventional, phase IV trial. Patients will be randomly assigned to either a static intraoperative fluid management (reflecting the current standard of care), with a limitation of 5ml/kg/h crystalloids from induction of anaesthesia to completed skin closure, or a dynamic goal-directed fluid management, where crystalloid fluids are only administered during surgery if PPV is above 12%.
Not provided
Not provided
Not provided
Not provided
|
| Norepinephrine (static group) | Drug | When during surgery SBP is below 100mmHg, if the 5ml/kg/h crystalloid limit is already reached, start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min). |
|
| Plasma-lyte (dynamic group) | Drug | Plasmalyte will be administered intravenously: (1) as a maintenance infusion 1 ml/kg/h (from anaesthesia induction until ICU/PACU discharge); (2) as a fluid bolus until PPV is below or equal to 12% or SBP is above 100mmHg. |
|
| Norepinephrine (dynamic group) | Drug | When during surgery SBP is below 100mmHg and PPV is below or equal to 12%: start or increase norepinephrine infusion until SBP is above 100mmHg (with a maximum dose of 0.2mcg/kg/min). When SBP is above 120mmHg: decrease the norepinephrine infusion rate until SBP is below 120mmHg. |
|
Cumulative perioperative norepinephrine dose (intraoperative and postoperative norepinephrine dose) |
| From anaesthesia induction until ICU/ PACU discharge, assessed up to 72 hours |
| Peri- and postoperative blood lactate levels | Peri- and postoperative blood lactate levels (hourly measurement during surgery, every four hours in the ICU until discharge) | From anaesthesia induction until ICU/ PACU discharge, assessed up to 72 hours |
| Percentage of time Systolic Blood Pressure (SBP) was above 100mmHg | Percentage of time SBP was above 100mmHg during surgery | During surgery, from anaesthesia induction until completed skin closure, assessed up to 12 hours |
| Postoperative free flap tissue oxygenation and blood perfusion (tissue oximetry) | Postoperative free flap perfusion monitored by near-infrared spectroscopy (NIRS) during ICU/PACU stay | From ICU admission until ICU/ PACU discharge, assessed up to 60 hours |
| Surgical complications | Surgical complications (e.g. total or partial flap loss, venous flap congestion, hematoma) assessed at ICU/PACU discharge and at hospital discharge | At ICU/ PACU discharge, assessed up to 60 hours and at hospital discharge, assessed up to 2 weeks |
| Length of stay | ICU/PACU length of stay (LOS) (hours) | From ICU admission until ICU/ PACU discharge, assessed up to 60 hours |
| ID | Term |
|---|---|
| D007022 | Hypotension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C012499 | Plasma-lyte 148 |
| D009638 | Norepinephrine |
| ID | Term |
|---|---|
| D004983 | Ethanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
| D000588 | Amines |
| D015306 | Biogenic Monoamines |
| D001679 | Biogenic Amines |
| D002395 | Catecholamines |
| D002396 | Catechols |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
Not provided
Not provided